BUSINESS WIRE
LAKE FOREST, Ill.--(
BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Food and Drug
Administration has granted approval for Akorn’s Abbreviated New Drug
Application (ANDA) for Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%.
Ciprofloxacin HCl Ophthalmic Solution is indicated for the treatment of
infections caused by microorganisms in corneal ulcers and
conjunctivitis. Annual sales for Ciprofloxacin HCl Ophthalmic Solution
are approximately $20 million, according to IMS sales data. Akorn
expects to launch Ciprofloxacin in 2009.
Arthur S. Przybyl, Akorn’s President and Chief Executive Officer stated,
“This product approval represents our 20th product approval
received in 2008, including our NDA approval for Akten™ and our joint
venture product approvals. I would like to personally congratulate our
Regulatory Affairs department for their efforts. Of the 20 product
approvals received in 2008, 8 were launched in 2008 and 10 are scheduled
for launch in the first half of 2009.”
About Akorn, Inc.
Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals.
Akorn has manufacturing facilities located in Decatur, Illinois and
Somerset, New Jersey and markets and distributes an extensive line of
hospital and ophthalmic pharmaceuticals. Additional information is
available at the Company’s website at www.akorn.com.
Materials in this press release may contain information that includes or
is based upon forward-looking statements within the meaning of the
Securities Litigation Reform Act of 1995. Forward-looking statements
give our expectations or forecasts of future events. You can identify
these statements by the fact that they do not relate strictly to
historical or current facts. They use words such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe," and other
words and terms of similar meaning in connection with a discussion of
future operating or financial performance. In particular, these include
statements relating to future steps we may take, prospective products,
future performance or results of current and anticipated products, sales
efforts, expenses, the outcome of contingencies such as legal
proceedings, and financial results.
Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by
inaccurate assumptions or by known or unknown risks and uncertainties.
Many such factors will be important in determining our actual future
results. Consequently, no forward-looking statement can be guaranteed.
Our actual results may vary materially, and there are not guarantees
about the performance of our stock.
Any forward-looking statements represent our expectations or forecasts
only as of the date they were made and should not be relied upon as
representing our expectations or forecasts as of any subsequent date. We
undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events or
otherwise, even if our expectations or forecasts change. You are
advised, however, to consult any further disclosures we make on related
subjects in our reports filed with the SEC. In particular, you should
read the discussion in the section entitled "Cautionary Statement
Regarding Forward-Looking Statements" in our most recent Annual Report
on Form 10-K, as it may be updated in subsequent reports filed with the
SEC. That discussion covers certain risks, uncertainties and possibly
inaccurate assumptions that could cause our actual results to differ
materially from expected and historical results. Other factors besides
those listed there could also adversely affect our results.